Deletion of the p53 Target Gene PUMA Prevents Bone Marrow Failure in a Dyskeratosis Congenita Mouse Model

Erlacher, M; Molnar, C; Weiss, JM; Bohler, S; Steinemann, D; Gohring, G; Villunger, A; Labi, V; Niemeyer, C; Egle, A BLOOD. 2018; 132:

Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma – AGMT_MM1

Ludwig, H; Ponisch, W; Knop, S; Schreder, M; Lechner, D; Hajek, R; Gunsilius, E; Krenosz, KJ; Petzer, A; Weisel, K; Einsele, H; Greil, R; Zojer, N BLOOD. 2018; 132:

Ixazomib in combination with carboplatin in pretreated women with advanced triple negative breast cancer, an ongoing phase I/II trial (AGMT MBC-10 trial)

Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Pusch, R; Voskova, D; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, CF; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R CANCER RES. 2018; 78(13):

Efficacy and safety of dabrafenib plus trametinib in patients with BRAF V600E-mutated biliary tract cancer and adenocarcinoma of the small intestine

Wainberg, Z; Lassen, U; Elez, E; Italiano, A; Curigliano, G; DeBraud, F; Prager, G; Greil, R; Stein, A; Angelica, F; Schellens, JHM; Wen, PY; Boran, AD; Mookerjee, B; Burgess, P; Rangwala, F; Subbiah, V EUR J CANCER. 2018; 103: E3-E4.

Evaluation of circulating cell-free DNA as a molecular monitoring tool in patients with metastatic cancer

Hufnagl, C; Leisch, M; Weiss, L; Melchardt, T; Moik, M; Geisberger, R; Asslaber, D; Steininger, P; Meissnitzer, T; Neureiter, D; Greil, R; Egle, A ONCOL RES TREAT. 2018; 41: 307-307.

Panitumumab-Associated Encephalopathy after Accidental Intra-Arterial Application through Dislocated Central Venous Access Device

Sellner, J; Pilz, G; Gschwandtner, G; Rosler, C; Schlick, K; Greil, R; Pikija, S ANN NEUROL. 2018; 84: S45-S45.

The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2-breast cancer patients from ABCSG 34

Dubsky, PC; Fesl, C; Singer, CF; Pfeiler, G; Kronenwett, R; Hubalek, M; Bartsch, R; Stoeger, H; Pichler, A; Petru, E; Bjelic-Radisic, V; Greil, R; Rudas, M; Tea, MKM; Wette, V; Petzner, AL; Sevelda, P; Egle, D; Fitzal, F; Exner, R; Jakesz, R; Balic, M; Tinchon, C; Bago-Horvath, Z; Lax, S; Regitnig, P; Gnant, M; Filipits, M CANCER RES. 2018; 78(4):

Contrast-enhanced MRI does not accurately predict pathologic complete response (pCR) after neoadjuvant chemotherapy in early or locally advanced breast cancer

Gampenrieder, SP; Peer, A; Weismann, C; Meissnitzer, M; Rinnerthaler, G; Webhofer, J; Westphal, T; Popovscaia, M; Meissnitzer, T; Reitsamer, R; Hauser-Kronberger, C; Egger, H; Hergan, K; Mlineritsch, B; Greil, R CANCER RES. 2018; 78(4):

Polyligand profiling differentiates cancer patients according to their benefit of treatment

Domenyuk, V; Gatalica, Z; Santhanam, R; Wei, XX; Stark, A; Kennedy, P; Toussaint, B; Levenberg, S; Wang, R; Xiao, N; Greil, R; Rinnerthaler, G; Gampenrieder, S; Heimberger, AB; Berry, DJ; Barker, A; Demetri, GD; Quackenbush, J; Marshall, JL; Poste, G; Vacirca, JL; Vidal, GA; Schwartzberg, LS; Halbert, DD; Voss, A; Miglarese, MR; Famulok, M; Mayer, G; Spetzler, D CANCER RES. 2018; 78(4):

Ixazomib in combination with carboplatin in pretreated women with advanced triple negative breast cancer, a phase I/II trial (AGMT MBC-10 trial)

Rinnerthaler, G; Gampenrieder, SP; Petzer, A; Pusch, R; Fridrik, M; Rossmann, D; Balic, M; Egle, D; Rumpold, H; Singer, C; Bartsch, R; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R CANCER RES. 2018; 78(4):